Baricitinib for Uveitis in Children with Juvenile Idiopathic Arthritis

We are studying whether the oral medication baricitinib is safe and effective for children aged 2 to under 18 with active uveitis linked to juvenile idiopathic arthritis. This research aims to improve treatment options for these young patients.

Confirmation phase (III)No Placebo Cost Reimbursement Standard Medicines Oral InjectionOphthalmologyRheumatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Adalimumab

Adalimumab is a biologic that blocks a key inflammatory protein (TNF) to reduce inflammation in autoimmune conditions like rheumatoid arthritis and Crohn's disease.

Baricitinib

Baricitinib is a substance that reduces immune-driven inflammation to treat rheumatoid arthritis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Charite Universitaetsmedizin Berlin KöR

Berlin, Germany

HELIOS Klinikum Berlin-Buch GmbH

Bernau bei Berlin, Germany

Hamburger Zentrum für Kinder- und Jugendrheumatologie

Kompetenzzentrum für Sklerodermie im Kindes- und Jugendalter

Hamburg, Germany

Sponsor: Eli Lilly & Co.

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.